ArticleBMC ophthalmology2025
Optical coherence tomography angiography in identifying aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOptical coherence tomography angiography (OCTA) has shown promise in assessing microvascular and structural alterations in the retina and optic nerve. This study primarily aimed to evaluate the utility of OCTA in distinguishing aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) patients from healthy controls (HC). Additionally, exploratory analyses were conducted to examine differences between AQP4-Ab + and AQP4-Ab-, all MOG-Ab-negative(double-seronegative) groups in NMOSD patients.
methodsWe retrospectively analyzed clinical data from NMOSD patients admitted to the Neurology Department of our First Hospital from January 2018 to December 2020. Patients were categorized into AQP4-Ab-positive (AQP4-Ab+) and double-seronegative groups, with an age-matched normal control group. OCTA examinations were conducted to compare differences in optic nerve fiber layer thickness, macular central thickness, optic disc, macular blood flow, and clinical characteristics among the three groups.
resultsThere were statistically significant gender differences among the three groups, with a higher proportion of females in the AQP4-Ab + group compared to the other two groups (P < 0.05). Structurally, significant differences were observed in all parameters between the AQP4-Ab + group and healthy controls (HC), as well as between the double-seronegative group and HC (all P < 0.05). Direct comparison between AQP4-Ab + and double-seronegative NMOSD patients revealed significant differences in specific OCTA parameters, including optic disc central vessel density (P < 0.001), inner optic disc ring vessel density (P = 0.010), inner optic disc ring superior vessel density (P = 0.008), and outer macular ring nasal vessel density (P = 0.042). However, most other OCTA parameters showed no statistically significant differences between the antibody-positive and antibody-negative subgroups (P > 0.05). The optic disc vessel density demonstrated the highest diagnostic efficiency overall, with the nasal side vessel density of the optic disc achieving an AUC of 0.829.
conclusionOCTA exhibits significant clinical utility in diagnosing AQP4-Ab + NMOSD. Differences between AQP4-Ab + and double-seronegative patients were explored and may provide further insight, although further research is required.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.